There's a 58% Chance of a Fed Rate Hike in October. These Are Stocks to Buy Anyway.

FOMC lift-off risk is rising: CME FedWatch implies a 44.1% chance of a rate hike in mid-September and 57.7% for late October. Against that backdrop, UnitedHealth is up 20% YTD, with Q2 earnings up ~54% YoY and management raising full-year guidance; JPMorgan’s Q2 net investment income was $25.6B (+10% YoY), which would likely benefit further if rates rise. Chevron is up over 20% YTD, supported by higher fuel prices tied to the Iran war, which may keep inflation elevated and help oil-linked earnings even if rates increase.

Analysis

This is less a “buy these stocks if rates rise” note than a signal that the market is repricing the policy path. The first-order move from a 25 bp hike is usually small; the real mechanism is whether higher rates are coming because inflation is sticky, which would tighten liquidity, flatten the curve, and pressure broad multiples. That dynamic is modestly supportive for CME, mixed for JPM, and mostly irrelevant for UNH. The immediate tape reaction should be limited unless the Fed shifts from a one-off hike to a sequence of hikes.

JPM’s benefit from higher short rates is real, but it is not linear: deposit beta, funding competition, and slower loan growth can dilute net interest income over 1-3 months, and a hotter inflation backdrop can eventually lift credit costs. CVX is better thought of as an energy-inflation hedge than a rate beneficiary; if the Fed is hiking because fuel prices are persistent, upstream cash flow holds up, but the equity can still face valuation compression if the market de-risks. That makes it more attractive in a relative-value or hedged structure than as an outright macro long.

The consensus is missing that UNH is the cleanest quality compounder here because its earnings drivers are mostly insulated from policy rates. If the market sells defensives alongside rate-sensitive names, that would likely be an overreaction and an opportunity. Over 6-18 months, the strongest structural winner from policy uncertainty may be CME, where trading/hedging demand rises when the front end of the curve becomes less predictable.

Key Decisions for Investors

• Long CME vs. short NDAQ for 1-3 months: prefer derivatives/hedging volume over cash-equity market exposure if rate-hike odds stay elevated; thesis breaks if policy uncertainty fades and front-end volatility compresses materially.
• Long JPM vs. short KRE into the next FOMC: the big-bank funding franchise should outperform regionals if the Fed tightens, but cap the trade if deposit costs start reaccelerating faster than asset yields.
• Buy CVX only as a hedged inflation trade, ideally via call spreads or against a broad market short; upside is tied to sustained crude strength, while the main risk is a quick unwind in oil once rate-hike odds fall.
• Do not treat UNH as a rates expression; use any macro-driven pullback as a watchlist entry point only if utilization and guidance remain intact. Falsifier: a deterioration in medical cost trends, not the Fed.